SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Atlas Venture Fund X, L.P. (Last) (First) (Middle) 400 TECHNOLOGY SQUARE, 10TH FLOOR (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/20/2020	3. Issuer Name and Ticker or Trading Symbol Kymera Therapeutics, Inc. [ KYMR ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	752,398	D(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Seed Convertible Preferred Stock	(2)	(2)	Common Stock	1,880,995	(2)	D(1)
Series A Convertible Preferred Stock	(2)	(2)	Common Stock	4,388,990	(2)	D(1)
Series B Convertible Preferred Stock	(2)	(2)	Common Stock	926,599	(2)	D(1)
Series C Convertible Preferred Stock	(2)	(2)	Common Stock	1,112,686	(2)	I	See footnote(3)

1. Name and Address of Reporting Person* Atlas Venture Fund X, L.P. (Last) (First) (Middle) 400 TECHNOLOGY SQUARE, 10TH FLOOR (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

1. Name and Address of Reporting Person* Atlas Venture Associates X, LLC (Last) (First) (Middle) 400 TECHNOLOGY SQ., 10TH FL (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

1. Name and Address of Reporting Person* ATLAS VENTURE ASSOCIATES X, L.P. (Last) (First) (Middle) 400 TECHNOLOGY SQ., 10TH FL (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

1. Name and Address of Reporting Person* Atlas Venture Associates Opportunity I, L.P. (Last) (First) (Middle) 400 TECHNOLOGY SQ., 10TH FL (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

1. Name and Address of Reporting Person* Atlas Venture Associates Opportunity I, LLC (Last) (First) (Middle) 400 TECHNOLOGY SQ., 10TH FL (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

1. Name and Address of Reporting Person* Atlas Venture Opportunity Fund I, L.P. (Last) (First) (Middle) 400 TECHNOLOGY SQ., 10TH FL (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)

Explanation of Responses:

1. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if its pecuniary interest therein, if any.

2. Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible into common stock on a one-for-1.5949 basis into the number of shares of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have no expiration date.

3. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVO I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Remarks:

	Atlas Venture Fund X, L.P., By: Atlas Venture Associates X, L.P., Its: General Partner, By: Atlas Venture Associates X, LLC, Its: General Partner, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	Atlas Venture Associates X, L.P., By: Atlas Venture Associates X, LLC, Its: General Partner, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	Atlas Venture Associates X, LLC, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	Atlas Venture Opportunity Fund I, L.P., By: Atlas Venture Associates Opportunity I, L.P., Its General Partner, By: Atlas Venture Associates Opportunity I, LLC, Its. General Partner, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	Atlas Venture Associates Opportunity I, L.P., By: Atlas Venture Associates Opportunity I, LLC, Its. General Partner, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	Atlas Venture Associates Opportunity I, LLC, By: /s/ Ommer Chohan, Ommer Chohan, Chief Financial Officer	08/20/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.